Higher Motor Activity in Schizophrenia Patients Treated With Olanzapine Versus Risperidone

被引:22
|
作者
Walther, Sebastian [1 ]
Horn, Helge [1 ]
Razavi, Nadja [1 ]
Koschorke, Philipp [1 ]
Wopfner, Alexander [1 ]
Mueller, Thomas J. [1 ]
Strik, Werner [1 ]
机构
[1] Univ Bern, Univ Hosp Psychiat, CH-3000 Bern 60, Switzerland
关键词
actigraphy; treatment effects; quantitative motor activity; ATYPICAL ANTIPSYCHOTICS; HALOPERIDOL; PSYCHOMOTOR; SYMPTOMS; SCALE; QUETIAPINE; MOVEMENTS; EFFICACY; SIGNS;
D O I
10.1097/JCP.0b013e3181d2ef6f
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There are indications that atypical antipsychotics differ in the probability of causing motor retardation. Whereas olanzapine seems to exert sedation, risperidone might slow patients because of parkinsonism or increased negative symptoms. Objective data on gross motor activity are not available. We present actigraphic data of 16 schizophrenia patients treated with olanzapine (mean dose, 21.1 mg/d) and 23 with risperidone (mean dose, 4.7 mg/d) to investigate possible differences in their effects on motor activity. Participants wore actigraphs continuously for 24 hours at the nondominant arm. Groups did not differ in age, Positive and Negative Syndrome Scale scores, duration of illness, and number of episodes. Patients treated with olanzapine had higher activity levels than those treated with risperidone (P = 0.024); this effect was robust and also present after covarying for chlorpromazine equivalents and Positive and Negative Syndrome Scale scores. Movement index (proportion of active episodes) and the average duration of immobility, however, failed to show any difference between groups. The results indicate that patients on olanzapine are more active during the day than patients on risperidone. It remains unclear whether this difference is due to subthreshold parkinsonism with risperidone or stronger beneficial effects of olanzapine on psychomotor slowing. Because the average duration of immobility remained unaffected, sedation is not likely to be the cause for the observed differences.
引用
收藏
页码:181 / 184
页数:4
相关论文
共 50 条
  • [31] Risperidone versus olanzapine for the treatment of schizophrenia: A cochrane systematic review
    Jayaram, M
    Hosalli, P
    Adams, CE
    SCHIZOPHRENIA RESEARCH, 2006, 81 : 85 - 85
  • [32] A comparison of olanzapine versus risperidone on improvement in negative symptoms and emotional discomfort in patients with schizophrenia
    Ahmed, S
    Zhang, F
    Lindborg, S
    Tohen, M
    Breier, A
    SCHIZOPHRENIA RESEARCH, 2003, 60 (01) : 270 - 270
  • [33] Weight gain in patients treated with risperidone and olanzapine
    Ganguli, R
    Brar, JS
    Ayrton, Z
    BIOLOGICAL PSYCHIATRY, 1998, 43 : 116S - 117S
  • [34] Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia
    D. Gothelf
    A. Apter
    J. Reidman
    A. Brand-Gothelf
    Y. Bloch
    G. Gal
    L. Kikinzon
    S. Tyano
    R. Weizman
    G. Ratzoni
    Journal of Neural Transmission, 2003, 110 : 545 - 560
  • [35] Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan
    Liu, CY
    Chiu, NY
    Wu, CK
    Yuan, LM
    Hsiao, MC
    Liao, O
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2003, 18 (01) : 49 - 51
  • [36] Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia
    Gothelf, D
    Apter, A
    Reidman, J
    Brand-Gothelf, A
    Bloch, Y
    Gal, G
    Kikinzon, L
    Tyano, S
    Weizman, R
    Ratzoni, G
    JOURNAL OF NEURAL TRANSMISSION, 2003, 110 (05) : 545 - 560
  • [37] A transcranial magnetic stimulation study of the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia
    Paul B. Fitzgerald
    Timothy L. Brown
    Jeff Z. Daskalakis
    J. Kulkarni
    Psychopharmacology, 2002, 162 : 74 - 81
  • [38] A transcranial magnetic stimulation study of the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia
    Fitsgerald, PB
    Brown, TL
    Daskalakis, ZJ
    Kulkarni, J
    PSYCHOPHARMACOLOGY, 2002, 162 (01) : 74 - 81
  • [39] Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol:: results of the EIRE study
    Bobes, J
    Rejas, J
    Garcia-Garcia, M
    Rico-Villademoros, F
    García-Portilla, MP
    Fernández, I
    Hernández, G
    SCHIZOPHRENIA RESEARCH, 2003, 62 (1-2) : 77 - 88
  • [40] Regional changes in alpha power reflect changes in symptoms in patients with schizophrenia, olanzapine and risperidone treated
    Edgar, JC
    LaNoue, M
    Heller, W
    Weisend, MP
    Miller, GA
    Morey, RA
    Cañive, JM
    SCHIZOPHRENIA RESEARCH, 2002, 53 (03) : 219 - 219